T he National Institute of Healthcare Research (NIHR) comprehensive clinical research network (CCRN) has supported an exponential proliferation of the numbers of intensive care studies on the national portfolio. In 2011/12 there were 58 active studies and a remarkable 40,000 participants in intensive care research. This is a cause for celebration, but has led many ICUs to experience potential research saturation and competition between studies. Competition can generate disagreements, disrupt teamwork, and potentially result in enrolment bias to studies, which could have unintended effects on the validity of research findings. It could also effectively limit the opportunity for patients to participate in research, or have this dictated by clinical or research staff which many would consider paternalistic. An obvious solution to this issue is to consider co-enrolment to multiple research studies. Co-enrolment can benefit funders (improved study efficiency), researchers (completing to target), participants (the opportunity to be exposed to novel treatments or procedures), and society (by ensuring studies complete 'on time and on target' to generate new evidence). Effective and equitable co-enrolment practices are also likely to maintain the network collaborations that have revolutionalised intensive care research in recent years.
Unsurprisingly, this issue is not unique to the UK. The ANZICS Clinical Trial Group (ANZICS-CTG), Canadian Critical Care Trials Group (CCCTG) and the ARDS Clinical Trials Network (ARDSnet) have all encountered this challenge. One solution is to use factorial trial designs, as widely used by ARDSnet. 1 However, this requires planning and funding a priori, which is rarely practical for a large diverse portfolio such as our UK intensive care portfolio. The alternative is to allow an individual to potentially be co-enroled to unrelated trials, assuming they fulfill the necessary criteria. This might occur simultaneously or, more often, at different stages of the critical illness 'journey.' A Round Table Conference in 2008 2 supported co-enrolment, concluding that effects on the primary analysis of either study were unlikely.
The ANZICS-CTGs have published a policy that encourages co-enrolment but draws attention to potential advantages and disadvantages. 3 The CCCTG guideline 4 pertains to randomised controlled trials (RCTs) of established therapies and specifically excludes co-enrolment into multiple industryinitiated trials or trials of new drugs or devices. A series of conditions are listed to be satisfied before allowing one ICU patient to be enrolled into two RCTs. These groups undertook a survey in 2007 5 that found over half of respondents had coenrolled patients; 46% reported that either their ICU and/or the local ethics board had guidelines or policies in place relating to co-enrolment. Interestingly, there was wide variation in approach. Despite general support among clinicians and researchers, the benefits of co-enrolment must be balanced against potential risks, including effects on statistical power, potential biological interactions, effects on adverse event rates, protocol compliance, and crucially, the potentially increased burdens for patients or their surrogate decision-makers (SDM).
To fully consider these issues and present comprehensive, clear, ethically sound guidance for the UK intensive care community a multidisciplinary group of research-active individuals has recently completed a guidance document, which is freely available through various sources including the ICS website. 6 The group used a mixture of literature review, expert opinion, brainstorming, and consensus discussion to write the guidance. A wide-ranging consultation by a diverse group of relevant stakeholders and experts (both UK and international) was undertaken before the final draft (see guidance document for full list). The group identified five key domains to consider, namely: study design and statistical issues, legal and ethical considerations, biological and scientific rationale, participant considerations, and logistical and organisational issues. These are considered in some detail, but a checklist ( Table 1) is intended to help researchers to systematically consider the issues for any two studies for which they are considering co-enrolment.
This editorial is intended to introduce the guidance and encourage researchers to use it. Several issues merit specific comment. Clearly, key factors to consider are the types of studies involved. Two or more observational studies, or an observational and interventional trial, are unlikely to have important design and statistical issues, or risk any biological interaction. For these situations, the issues relate largely to ethical approval, the burden to participants and SDMs, and logistical issues around study conduct and data collection. When co-enrolment to two interventional trials is considered, a careful consideration of potential biological interactions is required in relation to both outcome measures and adverse events. Both trials' investigator teams need to be satisfied that biological interaction is unlikely. Ideally this would happen at the design phase, but given this is rarely possible, the UK Critical Care Portfolio (and Specialty Group) offers a resource for the Chief Investigator of a new trial to search for potential co-enrolling trials, and a mechanism for contacting the relevant trial teams and ascertaining which ICUs may be participating in both studies. Importantly, it is also possible to identify other trials for which co-enrolment is not appropriate, and select participating centres with this in mind.
In relation to study design and statistical issues, high levels of co-enrolment could alter study power by changing factors such as baseline risk, control/usual care group management and outcomes, or intervention group outcomes. These effects will be most important if co-enrolment rates are not balanced or are very high, and have been considered in specific settings such as HIV, ARDS, and resuscitation. [7] [8] [9] [10] Modelling to assess likely effects on statistical power can be undertaken to account for various rates of co-enrolment. A CCCTG methodologist 11 used simulation with lower and higher control group mortality rates to show that unless co-enrolment rates were very high, ie
Study designs of both studies/trials 1. Could the processes and measures used in one study introduce bias by altering responses to those used in the other study?
2. Could the information obtained in one study alter clinical decision-making or treatment in a way that could introduce bias to the other study?
3. Are the two protocols compatible in terms of the allowed treatments, technologies, procedures, and treatment protocols?
4. Is the chance of an imbalance in the numbers of patients from one study allocated to the treatment groups in the other study high?
5. Could the inclusion in multiple research studies alter the characteristics of the control groups in a way that might alter study power and generalisability?
6. Should the numbers of patients being co-enrolled be tracked and reported back to each study management team? Logistical and organisational issues 19 . Have the management teams or Chief Investigators for both studies approved co-enrolment? 20. Does the ethics committee overseeing each study require to be informed of the planned co-enrolment? 21. Is a procedure needed to inform each study team when a co-enrolment occurs?
22. Do the screening procedures in ICUs in which co-enrolment is planned have a mechanism to track participation to different studies and flag when co-enrolment is possible?
23. Have procedures been put in place within ICUs where co-enrolment is possible to ensure adequate communication between individuals taking consent occurs, and ensure consistency and minimise patient or relative burden/stress? 24. If required, have local procedures been agreed to ensure documentation of co-enrolment within the patient record, and communication with each study management team?
25. If required, has a local strategy to guide the order of approach for different studies been agreed, and the circumstances in which an approach for co-enrolment will occur? 26. Has the potential burden of follow-up been considered by both study teams, and any procedures to minimise follow-up burden implemented? Table 1 Summary of issues to consider in relation to co-enrolment to multiple intensive care studies.
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greater than 50%, the effects of co-enrolment on study power and design are minimal. Although these rates of co-enrolment are unlikely for large RCTs, it seems sensible to track coenrolment in trial databases, to describe this in reports and if necessary undertake post hoc subgroup analyses. This emphasises the importance of formalising co-enrolment agreements, using templates similar to the one suggested in the guidance document, which ensure appropriate documentation and data collection. Paramount is consideration of the burden to patients and SDMs. The intensive care research environment is characterised by the vulnerability and incapacity of our patients, timesensitive recruitment windows, and high stress/anxiety levels of relatives and (therefore) SDMs. A valid moral argument is that patients should be offered all possible choices for treatment 12 and therefore the opportunity to participate in all available research. Conversely, co-enrolment decisions may be made by clinicians or investigators, which, although made with the best interest of the patient in mind, could be considered paternalistic. 13 Involving patients or SDMs in more than one trial clearly risks increasing participant burden at various stages of the consent, intervention, and follow-up process. Interestingly, research in paediatrics, neonatal care and cancer suggests co-enrolment is acceptable to patients and SDMs, [13] [14] [15] [16] but they may hold different views over the number of trials that should be offered 13, 15 and over consent. [17] [18] [19] The ability of SDMs to predict patients' views, at least in these scenario surveys, was limited with the complexity of each trial being an important reason for discrepancy. The decision to approach an individual patient or SDM inevitably relies heavily on the experience and judgment of the local research team.
The timing of approach (whether consecutively or bundled), the interval between approaches, and the coordination of different teams requires local commitment, sensitivity, and organisation. Likewise, assessing whether an individual participant or family can cope with the schedule of assessments, intervention procedures, and any follow-up needs careful judgment. A strength of the NIHR network is that it has funded a cohort of specialist research nurses working on a portfolio of research, thereby maximising coordination of activity and the acquisition of experience. Ideally, co-enrolling studies should share outcome assessment data to minimise follow-up burden wherever possible, although this may be logistically challenging.
Cook et al 20 recently published an insightful analysis of coenrolment to the multicentre multinational PROTECT study (3,746 patients recruited) comparing two different heparins for thromboprophylaxis. Co-enrolment occurred in 19% of participants, with half to another RCT. Co-enrolment was increased according to the phase of the trial, whether the centre was part of a network, SDM consent was given, the researcher' s experience in consent, and the patient' s illness severity. Importantly, co-enrolment rates were equal in each treatment arm, with no difference in adverse event and protocol violation rates. The overall trial result was the same when the co-enrolled patients were excluded. This transparent reporting of co-enrolment to a landmark intensive care trial provides both precedent and an example of best practice.
There is very little research describing current co-enrolment in UK intensive care research or the views of patients and SDMs. This should be a priority for the future, and would inform the guidance developed and improve it in the future. A clear understanding of the perspective and views of patients and SDMs would also be useful across the entire research process, from ethics committees to individual researchers taking consent.
Intensive care as a specialty has a reputation for teamwork, and intensive care research is no exception. The ICS Research Foundation, the Annual UK-Critical Care Research Forum, and the NIHR intensive care specialty group, are all examples of collaboration and teamwork between the UK intensive care research communities. Since its release, the co-enrolment guidance 6 has already triggered dialogue regarding potential coenrolment between existing large NIHR portfolio studies, and many have made decisions to co-enrol or not using the proposed systematic approach. Hopefully these processes will improve the efficiency, effectiveness, and quality of our research while keeping the interests of our patients and their families paramount at all times.
T he surge in popularity of 'smartphones' such as Apple' s iPhone among the medical profession has led to the development of numerous innovative software applications, or 'apps', for education and reference.
This particular application is aimed at anaesthetic trainees who are preparing for structured oral examinations -a popular format used worldwide by bodies ranging from the UK Royal College of Anaesthetists to the American Board of Anesthesia. Its goal is to provide a simple tool to generate and mark five minute oral exams.
A click on the app logo brings up a simple home screen (Figure 1a ). This leads the user onto a main page of 'Questions', with buttons on the bottom of the screen leading to other options (Figure 1b) . Once a topic is chosen, the main screen of the app is displayed, incorporating a marking scheme as shown in Figure 1c .
On clicking 'Start', a five minute timer begins. As questions are answered, points can be given simply by touching on the box next to the corresponding point. An alert sounds after four minutes, with a second alert at five minutes. Once the examination is finished, the total score is displayed.
As can be seen in the screenshot, questions can be allocated randomly or specifically. There are a few options in the 'Settings' menu, allowing the alerts to be toggled on and off, for instance.
This app is a useful tool for oral exam practice. It is simple to use, clearly portable, and provides a simple framework. In total, 14 questions are available on the initial free download, with 35 others available via an in-app purchase costing £5.99.
There are some downsides. Two people are required (an examiner and examinee), it is iPhone-only at present, and the question base is relatively limited for now. There are occasional bugs when rapidly switching from one screen to another.
Overall, this app is worth considering for anyone taking an anaesthetic oral examination. Hopefully similar apps aimed at intensive care examinations will be available in the near future!
App review ANAESTHESIA EXAMS by Medical Apps Ltd 2012
Developed by: James Plumb, Royal Cornwall Hospitals Trust and Vishal Dokia, Northampton General Hospital Available for iPhone, iPod Touch, and iPad Free download (£5.99 for additional content) 
